|
Dec 04 2023
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
|
|
Dec 01 2023
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
|
|
Nov 29 2023
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
|
|
Nov 24 2023
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
|
|
Nov 21 2023
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
|
|
Nov 20 2023
Gain Therapeutics Announces Proposed Public Offering
|
|
Nov 14 2023
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
|
|
Oct 04 2023
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
|
|
Sep 25 2023
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
|
|
Sep 20 2023
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
|
|
Sep 12 2023
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
|
|
Aug 28 2023
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
|
|
Aug 10 2023
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
|
|
Aug 07 2023
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
|
|
Jul 31 2023
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
|
|
Jun 01 2023
Gain Therapeutics to Present at the Jefferies Healthcare Conference
|
|
May 12 2023
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
|
|
May 03 2023
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
|
|
Apr 12 2023
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
|
|
Mar 29 2023
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
|
|
Mar 23 2023
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
|
|
Mar 22 2023
Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
|
|
Mar 21 2023
Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program
|
|
Mar 09 2023
Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
|
|
Feb 27 2023
Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium
|
|
Feb 02 2023
Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences
|
|
Jan 12 2023
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
|
